1. Home
  2. PRLD vs VIVK Comparison

PRLD vs VIVK Comparison

Compare PRLD & VIVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • VIVK
  • Stock Information
  • Founded
  • PRLD 2016
  • VIVK 2006
  • Country
  • PRLD United States
  • VIVK United States
  • Employees
  • PRLD N/A
  • VIVK N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • VIVK Oilfield Services/Equipment
  • Sector
  • PRLD Health Care
  • VIVK Energy
  • Exchange
  • PRLD Nasdaq
  • VIVK Nasdaq
  • Market Cap
  • PRLD 44.0M
  • VIVK 38.4M
  • IPO Year
  • PRLD 2020
  • VIVK N/A
  • Fundamental
  • Price
  • PRLD $1.03
  • VIVK $0.56
  • Analyst Decision
  • PRLD Strong Buy
  • VIVK
  • Analyst Count
  • PRLD 3
  • VIVK 0
  • Target Price
  • PRLD $4.00
  • VIVK N/A
  • AVG Volume (30 Days)
  • PRLD 231.3K
  • VIVK 246.1K
  • Earning Date
  • PRLD 11-05-2025
  • VIVK 08-19-2025
  • Dividend Yield
  • PRLD N/A
  • VIVK N/A
  • EPS Growth
  • PRLD N/A
  • VIVK N/A
  • EPS
  • PRLD N/A
  • VIVK N/A
  • Revenue
  • PRLD $7,000,000.00
  • VIVK $124,048,464.00
  • Revenue This Year
  • PRLD N/A
  • VIVK N/A
  • Revenue Next Year
  • PRLD N/A
  • VIVK N/A
  • P/E Ratio
  • PRLD N/A
  • VIVK N/A
  • Revenue Growth
  • PRLD N/A
  • VIVK 98.83
  • 52 Week Low
  • PRLD $0.61
  • VIVK $0.51
  • 52 Week High
  • PRLD $2.72
  • VIVK $1.89
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 45.61
  • VIVK 34.12
  • Support Level
  • PRLD $1.03
  • VIVK $0.51
  • Resistance Level
  • PRLD $1.26
  • VIVK $0.59
  • Average True Range (ATR)
  • PRLD 0.11
  • VIVK 0.08
  • MACD
  • PRLD -0.03
  • VIVK -0.01
  • Stochastic Oscillator
  • PRLD 10.34
  • VIVK 15.98

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About VIVK Vivakor Inc.

Vivakor Inc is a socially responsible operator, acquirer and developer of technologies and assets in the oil and gas industry, as well as related environmental solutions. It is focused on operating crude oil gathering, storage and transportation facilities, as well as contaminated soil remediation services. Company have two operating business segments: Transportation logistics services; Terminaling and storage facility product and services related to oil and gas production. Majority of revenue is from Terminaling and storage segment.

Share on Social Networks: